Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Study of Valbenazine for the Treatment of Chorea Associated With Huntington Disease in Canada

NCT06312189 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT06312189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06312189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Study of Valbenazine for the Treatment of Chorea Associated With Huntington Disease in Canada
Lead sponsor
Neurocrine Biosciences
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
April 24, 2024
Completion date
April 30, 2028
Enrollment
7 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chorea, huntington